161 related articles for article (PubMed ID: 20666674)
1. Cutaneous malignancies during treatment with efalizumab and infliximab: When temporal relationship does not mean causality.
Di Lernia V; Ricci C
J Dermatolog Treat; 2011 Aug; 22(4):229-32. PubMed ID: 20666674
[TBL] [Abstract][Full Text] [Related]
2. Treatments for psoriasis and the risk of malignancy.
Patel RV; Clark LN; Lebwohl M; Weinberg JM
J Am Acad Dermatol; 2009 Jun; 60(6):1001-17. PubMed ID: 19344980
[TBL] [Abstract][Full Text] [Related]
3. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study.
Marcil I; Stern RS
Lancet; 2001 Sep; 358(9287):1042-5. PubMed ID: 11589933
[TBL] [Abstract][Full Text] [Related]
4. CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab.
Mahé E; Descamps V; Grossin M; Fraitag S; Crickx B
Br J Dermatol; 2003 Jul; 149(1):170-3. PubMed ID: 12890213
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.
Costanzo A; Talamonti M; Botti E; Spallone G; Papoutsaki M; Chimenti S
Dermatology; 2009; 219(1):48-53. PubMed ID: 19372639
[TBL] [Abstract][Full Text] [Related]
6. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.
Asgari MM; Ray GT; Geier JL; Quesenberry CP
J Am Acad Dermatol; 2017 Apr; 76(4):632-638. PubMed ID: 28162854
[TBL] [Abstract][Full Text] [Related]
7. The status of biologic therapies in the treatment of moderate to severe psoriasis.
Menter A
Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
[TBL] [Abstract][Full Text] [Related]
8. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
Weinberg JM; Saini R
Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
[TBL] [Abstract][Full Text] [Related]
9. A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis.
Leonardi CL; Toth D; Cather JC; Langley RG; Werther W; Compton P; Kwon P; Wetherill G; Curtin F; Menter A
Dermatology; 2006; 213(3):204-14. PubMed ID: 17033169
[TBL] [Abstract][Full Text] [Related]
10. [Biologics in the treatment of psoriasis].
Dissemond J; Grabbe S
MMW Fortschr Med; 2006 Sep; 148(38):42-4. PubMed ID: 17036963
[TBL] [Abstract][Full Text] [Related]
11. Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporin treatment: response to long-term acitretin maintenance.
van de Kerkhof PC; de Rooij MJ
Br J Dermatol; 1997 Feb; 136(2):275-8. PubMed ID: 9068750
[TBL] [Abstract][Full Text] [Related]
12. Fulfilling an unmet need in psoriasis : do biologicals hold the key to improved tolerability?
Shear NH
Drug Saf; 2006; 29(1):49-66. PubMed ID: 16454534
[TBL] [Abstract][Full Text] [Related]
13. New development in the treatment of psoriasis--infliximab.
Pietrzak A; Chodorowska G; Jazienicka I; Junak-Bojarska A; Roliński J
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):322-7. PubMed ID: 15315008
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of systemic therapies for moderate to severe psoriasis.
Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
[TBL] [Abstract][Full Text] [Related]
15. [Infectious risk].
Calabuig E; Salavert M
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
[TBL] [Abstract][Full Text] [Related]
16. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
Weinberg JM; Saini R; Tutrone WD
J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
[TBL] [Abstract][Full Text] [Related]
17. Infliximab then efalizumab, the 'hit and run' approach does not work.
Barde C; Thielen AM; Saurat JH
Dermatology; 2008; 216(2):171-2. PubMed ID: 18216482
[TBL] [Abstract][Full Text] [Related]
18. The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis.
Young L; Czarnecki D
Australas J Dermatol; 2012 Feb; 53(1):57-60. PubMed ID: 22309334
[TBL] [Abstract][Full Text] [Related]
19. Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients.
Brunasso AM; Puntoni M; Salvini C; Delfino C; Curcic P; Gulia A; Massone C
Acta Derm Venereol; 2011 Jan; 91(1):44-9. PubMed ID: 21088813
[TBL] [Abstract][Full Text] [Related]
20. [Infliximab].
Herrera E; Habicheyn S
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():7-13. PubMed ID: 19080986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
